Cooler Heads News and Press

This SDVoyager interview highlights the personal journey that led Kate Dilligan to found Cooler Heads and the lessons she learned building a mission-driven company. Rather than focusing solely on business milestones, the conversation explores the motivation, challenges, and values behind the company's mission.

The article announces that the WVU Cancer Institute has expanded access to Cooler Heads Amma scalp cooling systems across its regional cancer centers, giving more patients the opportunity to reduce chemotherapy-induced hair loss closer to home.

Aetna recognizes the Cooler Heads Amma™ System as medically necessary for hair preservation during chemotherapy, marking an important step toward expanding access to scalp cooling. This recognition reinforces scalp cooling as a meaningful supportive care option that can help patients maintain hair and a sense of normalcy throughout treatment.

Aly Connors, a 31-year-old oncology nurse at Sharp Memorial Hospital, was diagnosed with stage 2B triple-negative breast cancer while planning her wedding and used scalp cooling to keep her hair through the ceremony, starting chemo just three weeks before the big day; she finished treatment in September, moved to immunotherapy, and is now back to hiking and yoga.

Article on New York Medicaid’s decision to cover scalp cooling marks a major health-equity milestone, expanding access to a previously costly cancer treatment that helps reduce chemotherapy-induced hair loss for underserved patients.

Cooler Heads, an innovative company dedicated to helping cancer patients manage the side effects of treatment, recently announced a groundbreaking development in New York's healthcare coverage.

The Cape Fear Valley article shares a patient story highlighting how scalp cooling  helped reduce chemotherapy-related hair loss. The piece emphasizes both the physical and emotional benefits, showing how maintaining hair can positively impact a patient’s confidence and overall experience during cancer care.

This article suggests that positive patient outcomes like Amma may signal strong product-market fit in oncology, helping drive adoption among providers and increasing interest from both patients and healthcare systems.